Menu
My ERA ERA beitreten

The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-KIDNEY trial

Suggestions
My Era ERA beitreten
Home | Video pages | Webcast | Non-Alcoholic Fatty Liver Disease and Chronic Kidney Disease: what is the link

Non-Alcoholic Fatty Liver Disease and Chronic Kidney Disease: what is the link

Teilen
https://www.youtube.com/watch?v=3dWbQ-D1src kopieren

Other e-seminars from Diabesity